What are Mass Spectrometry and Chromatography in Diagnostics and Why Do They Matter?
Mass spectrometry and chromatography are advanced analytical technologies used for the separation, identification, and quantification of chemical and biological compounds. In diagnostics, these technologies are commonly integrated into clinical workflows to support accurate analysis of complex patient samples.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has emerged as a preferred diagnostic technique due to its high specificity, sensitivity, and ability to support multiplex testing. These capabilities make it valuable for applications such as vitamin profiling, hormone analysis, therapeutic drug monitoring, newborn screening, infectious disease testing, and clinical toxicology.
According to BIS Research, the global mass spectrometry and chromatography in diagnostics market was valued at $834.0 million in 2025. The market is projected to reach $1,724.7 million by 2035, growing at a CAGR of 7.54% during 2025-2035.
Download the complete TOC and Request Sample Report
What’s Driving Growth in the Mass Spectrometry and Chromatography in Diagnostics Market?
Key Drivers:
• Continuous technological advancements in mass spectrometry and chromatography
• Growing adoption of LC-MS/MS in diagnostic laboratories
• Higher sensitivity and specificity compared to traditional immunoassays
• Increasing use in therapeutic drug monitoring, vitamin testing, and hormone profiling
• Rising integration of automated sample preparation systems
What Are the Challenges in the Mass Spectrometry and Chromatography in Diagnostics Market?
Key Challenges:• High initial setup cost of instruments
• Significant operational and maintenance expenses
• Shortage of skilled professionals
• Limited adoption in smaller laboratories and resource-constrained healthcare settings
• Complexity of workflow validation and regulatory compliance
What is the Recent Development in Mass Spectrometry and Chromatography in Diagnostics Market?
• July 2025: Waters Corporation and BD agreed to combine BD’s Biosciences & Diagnostic Solutions business with Waters Corporation to strengthen their liquid chromatography and mass spectrometry portfolio.
• June 2025: Bruker Corporation launched the proteoElute nanoflow LC system for ultra-sensitive multiomics and proteomics analyses.
• May 2025: Bruker Corporation launched the timsOmni mass spectrometer for deep, high-speed proteoform sequencing and post-translational modification analysis.
• April 2025: Bruker Corporation made a majority investment in RECIPE Chemicals + Instruments to strengthen its clinical mass spectrometry portfolio.
Market Segmentation: Where Are Growth Opportunities?
By Product Type
• Sample Preparation
• Mass Spectrometry and Chromatography
By Application Type
• Therapeutic Drug Monitoring
• Vitamins
• Hormones
• Methylmalonic Acid
• Immunosuppressants
• Clinical Toxicology
• Others
By Sample Type
• Blood
• Urine
• Serum
• Plasma
• Saliva
By Testing Type
• Laboratory-Developed Tests
• Commercial Assays
By Region
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o Spain
o Italy
o France
o Rest-of-Europe
• Asia-Pacific
o China
o Japan
o India
o Rest-of-Asia-Pacific
• Latin America
o Brazil
o Mexico
o Rest-of-Latin America
• Middle East and Africa
o GCC Countries
o South Africa
o Rest-of-Middle East and Africa
